E-LIB Suche - Ergebnisse für: Lafuma, A

1

NAFLD/NASH patients with compensated cirrhosis (CC) had a h..:

Boursier, J. ; Fabron, C. ; Lafuma, A..
Journal of Hepatology. 68 (2018) - p. S820 , 2018

Link: https://doi.org/10.1016/..

2

PCN178 - COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE..:

Robert, J. ; Culine, S. ; Roupret, M....
Value in Health. 21 (2018) - p. S44 , 2018

Link: https://doi.org/10.1016/..

3

PCN105 - ECONOMIC BURDEN OF RECURRENT AND/OR METASTATIC SQU..:

Lafuma, A. ; Cotté, F. ; Le Tourneau, C....
Value in Health. 21 (2018) - p. S32 , 2018

Link: https://doi.org/10.1016/..

4

Analyse coût-efficacité de l'aripiprazole injectable à libé..:

Gozlan, G. ; Lecardeur, L. ; Monfort, A.-S....
L'Encéphale. 44 (2018) 6 - p. 496-503 , 2018

Link: https://doi.org/10.1016/..

5

NASH/NAFLD patients with end stage liver disease experience..:

Boursier, J. ; Fabron, C. ; Lafuma, A..
Journal of Hepatology. 68 (2018) - p. S238-S239 , 2018

Link: https://doi.org/10.1016/..

6

PMS65 - MYOTONIC DISORDERS: ANALYSIS FROM THE FRENCH DRG-BA..:

Mahi, L. ; Lafuma, A. ; Torreton, E...
Value in Health. 21 (2018) - p. S298 , 2018

Link: https://doi.org/10.1016/..

7

Cost Of Hospitalizations For Nontuberculous Mycobacterial P..:

Lafuma, A ; Emery, C ; Bureau, I..
Value in Health. 20 (2017) 9 - p. A511-A512 , 2017

Link: https://doi.org/10.1016/..

8

Costs of Chemotherapy-Induced Adverse Events in Head and Ne..:

Lafuma, A ; Cotte, F ; Le Tourneau, C...
Value in Health. 20 (2017) 9 - p. A407 , 2017

Link: https://doi.org/10.1016/..

9

Management And Cost Analysis Of Cancer Patients Treated Wit..:

Tilleul, P ; Jacot, W ; Emery, C...
Value in Health. 20 (2017) 9 - p. A463 , 2017

Link: https://doi.org/10.1016/..

10

The 21-Gene Assay In The Decision Impact Assessment of ER+,..:

Mouysset, J ; Laplaige, P ; Fignon, A...
Value in Health. 19 (2016) 7 - p. A685 , 2016

Link: https://doi.org/10.1016/..

11

Real World Utilization of Biological Agents in Rheumatoid A..:

Laurendeau, C ; Lafuma, A ; Trancart, M
Value in Health. 19 (2016) 7 - p. A546 , 2016

Link: https://doi.org/10.1016/..

12

French Prospective Multi-Center Cohort on The Decision Impa..:

Michaud, P. ; Mouysset, J. ; Dohollou, N....
Value in Health. 19 (2016) 3 - p. A297 , 2016

Link: https://doi.org/10.1016/..

13

Cost-effectiveness model comparing dual-mobility to fixed-b..:

Epinette, J.-A. ; Lafuma, A. ; Robert, J..
Orthopaedics & Traumatology: Surgery & Research. 102 (2016) 2 - p. 143-148 , 2016

Link: https://doi.org/10.1016/..

14

Budget Impact Of Ulipristal Acetate 5mg In Pre-Operative Tr..:

Trancart, M ; Lehmann, M ; Lafuma, A
Value in Health. 19 (2016) 7 - p. A401 , 2016

Link: https://doi.org/10.1016/..

15

Modèle d'impact budgétaire des biosimilaires d'etanercept d..:

Trancart, M. ; Lafuma, A. ; Laurendeau, C..
Revue du Rhumatisme. 83 (2016) - p. A301 , 2016

Link: https://doi.org/10.1016/..